Development of a Scalable Synthetic Route and a Crystal Morphology Characterization Method for the PDE4B Inhibitor HY-072808

An improved synthesis of HY-072808 ( 1 ), a highly potent and selective PDE4B inhibitor developed as a clinical candidate, is reported, achieving an overall yield of 42.9% and a purity of 99.98%. Starting from readily available and inexpensive 4-(trifluoromethyl)aniline ( 10 ) and 2-bromo-5-hydroxybenzaldehyde ( 5 ), HY-072808 was effectively and conveniently synthesized without chromatographic purification in any steps. Key improvements include enhanced control over impurity formation, increased productivity of the S N Ar reaction, efficient purification of the product through acidification, effective removal of palladium via recrystallization, and a reliable method for identifying the crystal morphology. This process has been successfully scaled up to produce over 3 kg of HY-072808.